The Global Antimicrobial Resistance Research and Development Hub, or Global AMR R&D Hub for short, is an initiative of international R&D funders to help combat antimicrobial drug resistance. The hub was officially launched during the World Health Assembly in 2018, a year after the G20 leaders decided to reinforce global cooperation in the fight against resistant germs.
The hub's goal is to identify key research and development tasks and to provide information, which supports decision-making regarding the distribution of funding. Members will continue to make their funding decisions independently. However, all involved stakeholders will coordinate with each other on their research activities. This approach should lead to a better use of resources and promote joint projects: for example, projects in which new diagnostic measures and active compounds against resistant pathogens that are no longer affected by common antibiotics are developed. Although these substances are urgently needed, the development of new drugs is tedious, costly and offers little incentive for the pharmaceutical industry. Consequently, public research funding is important and must be promoted for the benefit of patients.
18 government and non-governmental organisations are currently active in the Global AMR R & D Hub, including Russia, China, US, and France, the Bill & Melinda Gates Foundation, Wellcome, and the European Commission. The Federal Ministry of Education and Research (BMBF) was instrumental in setting up the hub. The office is located in Berlin – under the roof of the DZIF.